Haemodialysis fMRI Salt Appetite Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-17

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Assessing how the rapid removal of salt and water by haemodialysis alters regional brain activity (by measurement of the brain blood oxygen level-dependent (BOLD) signal using functional MRI) during tasting of soup of differing salt concentrations.
2. Identify differences in the brain response to salt taste pre- and post-haemodialysis between haemodialysis patients who are either able or unable to control between dialysis weight gain

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dietary Sodium (DS) Intervention to Reduce Volume Overload and Tissue Sodium in Magnetic Resonance Imaging (MRI) for Hemodialysis (HD) Patients

NCT03189758

Kidney Failure, Chronic Dietary Modification

UNKNOWN NA

Dietary Sodium-Restriction (DIS) and Renal Meals (RM) for Hemodialysis (HD)(DISaRM-HD)

NCT04991441

Kidney Failure, Chronic Dietary Modification

UNKNOWN NA

Hemodialysis and Wanting for Protein-rich Foods

NCT02221050

Renal Failure

COMPLETED

Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy

NCT03119818

End-Stage Renal Disease (ESRD)

COMPLETED NA

Fluid Intake After Hemodialysis

NCT04721652

Chronic Kidney Disease Requiring Chronic Dialysis Interdialytic Weight Gain

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HeMSA Study Phase 2 Up to 20 male, haemodialysis patient who have average %IDWG \>4% will be recruited with the target, to proceed to scanning, of 14 patients. Following consent the patients will complete questionnaires (including Salt intake questionnaire - DSQ (Gkza and Davenport, 2017), Edinburgh handedness questionnaire (Oldfield, 1971), MRI checklist) and undergo salt taste preference and threshold testing during a 1 hour session prior to dialysis. The purpose of this visit is to establish the tasteless solution and 2 soup salt concentrations to be used in the salt taste fMRI paradigm, obtain baseline data regarding estimate of salt intake and ensure MRI is safe for this patient.

Patients will then attend 2 MRI scanning visits at the Hammersmith Hospital Imperial Campus, one the morning immediately before haemodialysis and one the morning after haemodialysis. Prior to the MRI session, at the Imperial College Clinical Research Facility, the patient will undergo various clinical assessments and have venous blood samples taken. The MRI will be undertaken at the Imperial College Clinical Imaging Facility using a Siemens 3T Verio scanner. During the scan subjects will taste, via a taste delivery system, aliquots of tasteless solution, sucralose, and 2 soup with different concentrations of salt. Solutions will be delivered in a block design.

HeMSA Study Phase 3 3 groups (healthy controls, haemodialysis (HD) patients with %IDWG \<4%, haemodialysis patients with %IDWG \>4% - patients froms phase 2 will contribute to the latter group) Protocol will follow that for HeMSA Phase 2. Healthy controls will also have 2 study visits at a similar period apart to the HD participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dialysis Excess Interdialytic Weight Gain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Control

Healthy control

No interventions assigned to this group

Haemodialysis %IDWG >4%

Patient on regular haemodialysis with average IDWG \>4%

haemodialysis

Intervention Type PROCEDURE

Routine haemodialysis session

Haemodialysis %IDWG <4%

Patient on regular haemodialysis with average IDWG \<4%

haemodialysis

Intervention Type PROCEDURE

Routine haemodialysis session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

haemodialysis

Routine haemodialysis session

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All participants:

* Male
* Aged 18-65 years
* Non-smoker (ex-smokers allowed)
* Right handed (able to use a right handed response button)
* Able to tolerate 1 hour MRI scanning session

For haemodialysis patients:

* Established on haemodialysis for more than 6 months
* Urine output \<200ml/24 hours
* Average (over the past month) interdialytic weight gain:

1. Main phase 2: \>4 %IDWG
2. Main phase 3: \<4 or \>4 %IDWG

Exclusion Criteria

* Type 1 or type 2 diabetes mellitus
* Current smoker
* Uncontrolled depression (change in use of anti-depressants in last 3 months, or BDI-II score \>28/63)
* Neurological disorder (Parkinson's disease, serious cerebrovascular disease, epilepsy, moderate-severe traumatic brain injury, dementia)
* Previous bariatric surgery
* Inflammatory state (CRP \>20 on routine dialysis blood tests)
* Acute infective illness
* Significant current or past medical or psychiatric history, or use of medications, that, in the opinion of the Investigators, contraindicates their participation, due to influence on outcome measures.
* Patients lacking capacity or unable to consent and non-English language speakers
* Contra-indication to MRI imaging e.g. metal insert, pacemaker
* Claustrophobia
* Patients currently participating in an active CTIMP trial, or within 4 half-lives of last administration of CTIMP product
* Serious mental illness (e.g. bipolar disorder, schizophrenia)
* Current alcohol or drug dependence

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes